1
|
Jawahir S, Mohamad Anuar NN, Sheikh Abdullah SF, Silvernayagam S, Tan EH. Perception of nurses on the practice environment: experience from Malaysia. Med J Malaysia 2021; 76:73-79. [PMID: 33510113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
INTRODUCTION Positive professional practice environments are crucial to safeguard a healthy and safe working conditions for health workforce, including nurses; so as to ensure provision of quality healthcare and safety of patient. METHODS This was a cross-sectional study to assess nurses' perceptions towards nursing practice environment and factors associated with their perceptions. A validated Practice Environment Scale of the Nursing Work Index (PESNWI) questionnaire was administered to nurses working in two Ministry of Health hospitals. The questionnaire comprises of five subscales: Participation, Foundation, Managers Support, Workforce Adequacy and Physician/Nurse Relations. Mean scores of >2.50 were considered as favourable, and ≤2.50 were considered as unfavourable. Simple linear and multiple linear regression analysis were employed to identify factors associated with their perceptions. Analysis was carried out using STATA version 14.0. RESULTS A total of 366 respondents took part in the study, with a response rate of 98.4%. Majority were working shift (89.6%) and working extended hours (62.3%). In general, the nursing practice environments were rated as favourable. Overall mean score was 2.90±0.03 and four out of five subscales' mean scores were >2.50. Foundation for quality nursing care was perceived as the most favourable subscale, while workforce adequacy was perceived as the least favourable. There were statistically significant association between working extended hours, doing double shift and working during day off with perceived unfavourable workforce adequacy. CONCLUSION Nursing practice environment was perceived as favourable in the studied hospitals. Policy makers, service providers, and hospital managers could explore further on human resource planning and management of nursing personnel to tackle the issue of nurse staffing in the country.
Collapse
Affiliation(s)
- S Jawahir
- Institute for Health Systems Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Shah Alam, Selangor, Malaysia.
| | - N N Mohamad Anuar
- Hospital Putrajaya, Ministry of Health Malaysia, Putrajaya, Malaysia
| | - S F Sheikh Abdullah
- Nursing Division, Ministry of Health Malaysia, Federal Government Administrative Centre, Putrajaya, Malaysia
| | - S Silvernayagam
- Hospital Ampang, Ministry of Health Malaysia, Ampang, Selangor, Malaysia
| | - E H Tan
- Institute for Health Systems Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Shah Alam, Selangor, Malaysia
| |
Collapse
|
2
|
Cheah AKW, Kangkorn T, Tan EH, Loo ML, Chong SJ. The validation study on a three-dimensional burn estimation smart-phone application: accurate, free and fast? Burns Trauma 2018; 6:7. [PMID: 29497619 PMCID: PMC5828346 DOI: 10.1186/s41038-018-0109-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/18/2017] [Accepted: 01/24/2018] [Indexed: 11/16/2022]
Abstract
Background Accurate total body surface area burned (TBSAB) estimation is a crucial aspect of early burn management. It helps guide resuscitation and is essential in the calculation of fluid requirements. Conventional methods of estimation can often lead to large discrepancies in burn percentage estimation. We aim to compare a new method of TBSAB estimation using a three-dimensional smart-phone application named 3D Burn Resuscitation (3D Burn) against conventional methods of estimation—Rule of Palm, Rule of Nines and the Lund and Browder chart. Methods Three volunteer subjects were moulaged with simulated burn injuries of 25%, 30% and 35% total body surface area (TBSA), respectively. Various healthcare workers were invited to use both the 3D Burn application as well as the conventional methods stated above to estimate the volunteer subjects’ burn percentages. Results Collective relative estimations across the groups showed that when used, the Rule of Palm, Rule of Nines and the Lund and Browder chart all over-estimated burns area by an average of 10.6%, 19.7%, and 8.3% TBSA, respectively, while the 3D Burn application under-estimated burns by an average of 1.9%. There was a statistically significant difference between the 3D Burn application estimations versus all three other modalities (p < 0.05). Time of using the application was found to be significantly longer than traditional methods of estimation. Conclusions The 3D Burn application, although slower, allowed more accurate TBSAB measurements when compared to conventional methods. The validation study has shown that the 3D Burn application is useful in improving the accuracy of TBSAB measurement. Further studies are warranted, and there are plans to repeat the above study in a different centre overseas as part of a multi-centre study, with a view of progressing to a prospective study that compares the accuracy of the 3D Burn application against conventional methods on actual burn patients.
Collapse
Affiliation(s)
- A K W Cheah
- 1Department of Plastic, Reconstructive and Aesthetic Surgery, Singapore General Hospital, 1 Outram Road, Bukit Merah, Singapore
| | - T Kangkorn
- 2Department of Plastic and Reconstructive Surgery, Chonburi Hospital, 69 Sukhumvit Road, Muang Chonburi, Thailand
| | - E H Tan
- Navy Medical Service, Republic of Singapore Navy, 210 Tanah Merah Coast Road, Singapore, Singapore
| | - M L Loo
- Navy Medical Service, Republic of Singapore Navy, 210 Tanah Merah Coast Road, Singapore, Singapore
| | - S J Chong
- 1Department of Plastic, Reconstructive and Aesthetic Surgery, Singapore General Hospital, 1 Outram Road, Bukit Merah, Singapore
| |
Collapse
|
3
|
Dickgreber N, Yang JCH, Ahn MJ, Halmos B, Hirsh V, Hochmair M, Levy B, de Marinis F, Mok T, O'Byrne K, Okamoto I, Schuler M, Sebastian M, Shah R, Tan EH, Yamamoto N, Märten A, Massey D, Wind S, Carbone D. Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). Pneumologie 2016. [DOI: 10.1055/s-0036-1572233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Hsu AAL, Tan EH, Takano AMP. Lower Respiratory Tract Adenoid Cystic Carcinoma: Its Management in the Past Decades. Clin Oncol (R Coll Radiol) 2015; 27:732-40. [PMID: 26160258 DOI: 10.1016/j.clon.2015.06.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Revised: 05/20/2015] [Accepted: 06/15/2015] [Indexed: 12/25/2022]
Abstract
AIMS Adenoid cystic carcinoma of the lower respiratory tract is a rare indolent neoplasm with prolonged survival, propensity for recurrences and metastasis years after initial therapy. We aim to study a 1,700-bed single tertiary academic hospital's long-term experience with ACC of the lower respiratory tract from the larynx to the lungs and review published literature on this subject. MATERIALS AND METHODS We analysed the clinicopathology, treatment options and outcome in 33 patients and reviewed the published literature over the last five decades. RESULTS The tumour has no gender predilection, a peak incidence in the fifth decade and is not related to smoking. Insidious symptoms are often treated as benign obstructive airway disease and infection; negative signs and normal chest X-rays delayed diagnosis. The tumour was distributed most commonly in the trachea followed by main bronchi, lobar bronchi and larynx. About 22% of patients required emergent bronchoscopic intervention to secure airway patency before definitive therapy with surgery or/and radiotherapy. A high proportion of resected specimens had positive margins. Overall survival and disease-free survival rates at 5 years were 81 and 62%, respectively, and at 10 years 70 and 54%, respectively. Prolonged good palliation was achieved for patients with unresectable lesions with radiation and wide armamentarium of endoscopic therapy. CONCLUSIONS In time, many patients eventually succumb to this disease. However, advances in medical skill and technology have prolonged survival while maintaining a good quality of life. Adenoid cystic carcinoma of the respiratory tract is a chronic life-long disease that may require interval intensive therapy. The challenge is to find the best therapeutic regimen aiming for a 'true' cure. Further study on the mutational landscape of adenoid cystic carcinoma may provide potential avenues for novel treatments to address a chemoresistant cancer.
Collapse
Affiliation(s)
- A A L Hsu
- Department of Respiratory & Critical Care Medicine, Singapore General Hospital, Singapore.
| | - E H Tan
- Department of Medical Oncology, National Cancer Centre, SingHealth, Singapore
| | - A M P Takano
- Department of Pathology, Singapore General Hospital, Singapore
| |
Collapse
|
5
|
Tan EH, Morton JP, Timpson P, Tucci P, Melino G, Flores ER, Sansom OJ, Vousden KH, Muller PAJ. Functions of TAp63 and p53 in restraining the development of metastatic cancer. Oncogene 2014; 33:3325-33. [PMID: 23873029 PMCID: PMC4181588 DOI: 10.1038/onc.2013.287] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2013] [Revised: 05/22/2013] [Accepted: 06/07/2013] [Indexed: 12/25/2022]
Abstract
Many tumours harbour mutations in the p53 tumour-suppressor gene that result in the expression of a mutant p53 protein. This mutant p53 protein has, in most cases, lost wild-type transcriptional activity and can also acquire novel functions in promoting invasion and metastasis. One of the mechanisms underlying these novel functions involves the ability of the mutant p53 to interfere with other transcription factors, including the p53 family protein TAp63. To investigate whether simultaneous depletion of both p53 and TAp63 can recapitulate the effect of mutant p53 expression in vivo, we used a mouse model of pancreatic cancer in which the expression of mutant p53 resulted in the rapid appearance of primary tumours and metastases. As shown previously, loss of one allele of wild-type (WT) p53 accelerated tumour development. A change of one WT p53 allele into mutant p53 did not further accelerate tumour development, but did promote the formation of metastasis. By contrast, loss of TAp63 did not significantly accelerate tumour development or metastasis. However, simultaneous depletion of p53 and TAp63 led to both rapid tumour development and metastatic potential, although the incidence of metastases remained lower than that seen in mutant p53-expressing tumours. TAp63/p53-null cells derived from these mice also showed an enhanced ability to scatter and invade in tissue culture as was observed in mutant p53 cells. These data suggest that depletion of TAp63 in a p53-null tumour can promote metastasis and recapitulate-to some extent-the consequences of mutant p53 expression.
Collapse
Affiliation(s)
- EH Tan
- Cancer Research UK Beatson Institute, Glasgow, UK
| | - JP Morton
- Cancer Research UK Beatson Institute, Glasgow, UK
| | - P Timpson
- Cancer Research UK Beatson Institute, Glasgow, UK
- The Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Cancer Program, Sydney, Australia
| | - P Tucci
- Medical Research Council, Toxicology Unit, Leicester University, Leicester, UK
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende (CS), Italy
| | - G Melino
- Medical Research Council, Toxicology Unit, Leicester University, Leicester, UK
- Biochemistry Laboratory, Istituto Dermopatico dell’Immacolata, Istituto di Ricovero e Cura a Carattere Scientifico and University of Rome, “Tor Vergata,” Rome, Italy
| | - ER Flores
- Department of Biochemistry and Molecular Biology, Graduate School of Biomedical Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
| | - OJ Sansom
- Cancer Research UK Beatson Institute, Glasgow, UK
| | - KH Vousden
- Cancer Research UK Beatson Institute, Glasgow, UK
| | - PAJ Muller
- Cancer Research UK Beatson Institute, Glasgow, UK
| |
Collapse
|
6
|
Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JSK, Blasinska-Morawiec M, Serwatowski P, Krzakowski M, Jassem J, Tan EH, Benner RJ, Ingrosso A, Meech SJ, Readett D, Thatcher N. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2012; 23:72-77. [PMID: 21464154 DOI: 10.1093/annonc/mdr030] [Citation(s) in RCA: 103] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND This open-label phase III study assessed the addition of Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 to gemcitabine/cisplatin chemotherapy in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Chemotherapy-naive patients with stage IIIB or IV NSCLC were randomized (1:1) to receive six or fewer 3-week cycles of i.v. gemcitabine (1250 mg/m2 on days 1 and 8) and cisplatin alone (75 mg/m2 on day 1, control arm) or combined with s.c. PF-3512676 0.2 mg/kg on days 8 and 15 of each chemotherapy cycle and weekly thereafter until progression or unacceptable toxicity (experimental arm). No crossover was planned. The primary end point was overall survival (OS). RESULTS A total of 839 patients were randomized. Baseline demographics were well balanced. Median OS (11.0 versus 10.7 months; P=0.98) and median progression-free survival (PFS) (both 5.1 months) were similar between groups. Grade≥3 hematologic adverse events (AEs), injection-site reactions, and influenza-like symptoms were more frequently reported among patients receiving PF-3512676. At the first-interim analysis, the Data Safety Monitoring Committee recommended study discontinuation. Administration of PF-3512676 was halted based on efficacy futility and increased grade≥3 AEs (experimental arm). CONCLUSIONS Addition of PF-3512676 to gemcitabine/cisplatin chemotherapy did not improve OS or PFS but did increase toxicity.
Collapse
Affiliation(s)
- C Manegold
- Interdisciplinary Thoracic Oncology, Department of Surgery, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany.
| | - N van Zandwijk
- Bernie Banton Centre, University of Sydney, Sydney, Australia
| | - A Szczesna
- 3rd Department, Regional Lung Diseases Hospital, Otwock, Poland
| | - P Zatloukal
- 3rd Faculty of Medicine, Charles University, Faculty Hospital Bulovka and Postgraduate Medical Institute, Prague, Czech Republic
| | - J S K Au
- Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong
| | | | - P Serwatowski
- Chemotherapy Department, Specialistic Hospital Named After Professor A. Sokolowski, Szczecin-Zdunowo
| | - M Krzakowski
- Lung and Thoracic Tumours Department, Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw
| | - J Jassem
- Department of Oncology and Radiology, Medical University of Gdansk, Gdansk, Poland
| | - E H Tan
- Department of Medical Oncology, National Cancer Centre, Singapore
| | - R J Benner
- Pfizer Global Research and Development, New London, USA
| | - A Ingrosso
- Pfizer Global Research and Development, Milan, Italy
| | - S J Meech
- Pfizer Global Research and Development, New London, USA
| | - D Readett
- Pfizer Global Research and Development, New London, USA
| | - N Thatcher
- Department of Medical Oncology, Christie Hospital, Manchester, UK
| |
Collapse
|
7
|
Kao YH, Tan EH, Lim KY, Ng CE, Goh SW. Yttrium-90 internal pair production imaging using first generation PET/CT provides high-resolution images for qualitative diagnostic purposes. Br J Radiol 2011; 85:1018-9. [PMID: 21976634 DOI: 10.1259/bjr/33524085] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Yttrium-90 ((90)Y) internal pair production can be imaged by positron emission tomography (PET)/CT and is superior to bremsstrahlung single-photon emission CT/CT for evaluating hepatic (90)Y microsphere biodistribution. We illustrate a case of (90)Y imaging using first generation PET/CT technology, producing high-quality images for qualitative diagnostic purposes.
Collapse
Affiliation(s)
- Y H Kao
- Department of Nuclear Medicine and PET, Singapore General Hospital, Singapore.
| | | | | | | | | |
Collapse
|
8
|
Affiliation(s)
- E. H. Tan
- Senior Structural Engineer, HDR Inc., Minneapolis, MN 55416-3636
- Professor, Dept. of Civil and Environmental Engineering, Univ. of California, Irvine, CA 92697-2175 (corresponding author)
| | - L. Z. Sun
- Senior Structural Engineer, HDR Inc., Minneapolis, MN 55416-3636
- Professor, Dept. of Civil and Environmental Engineering, Univ. of California, Irvine, CA 92697-2175 (corresponding author)
| |
Collapse
|
9
|
Chia WK, Wang WW, Teo M, Tai WM, Lim WT, Tan EH, Leong SS, Sun L, Chen JJ, Gottschalk S, Toh HC. A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol 2011; 23:997-1005. [PMID: 21821548 DOI: 10.1093/annonc/mdr341] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Individuals with metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) continue to have poor outcomes. To evaluate the ability of a dendritic cell (DC) vaccine to target subdominant EBV antigens LMP1 and LMP2 expressed by NPC cells, we vaccinated patients using autologous DCs transduced with an adenovirus encoding a truncated LMP1 (ΔLMP1) and full-length LMP2 (Ad-ΔLMP1-LMP2). MATERIALS AND METHODS Sixteen subjects with metastatic NPC received Ad-ΔLMP1-LMP2 DC vaccines i.d. biweekly for up to five doses. Toxicity, immune responses and clinical responses were determined. RESULTS Most patients had extensive disease, with a median of three visceral sites of involvement (range 1-7). No significant toxicity was observed. Ad-ΔLMP1-LMP2 DCs induced delayed type hypersensitivity responses in 9 out of 12 patients, but although these DCs activated LMP1/2-specific T cells in vitro, no such increase in the frequency of peripheral LMP1/2-specific T cells was detected. Three patients had clinical responses including one with partial response (for 7½ months) and two with stable disease (for 6½ and 7½ months). CONCLUSIONS Ad-ΔLMP1-LMP2 transduced DCs can be successfully generated and safely administered to patients with advanced NPC. Since efficacy was limited, future studies should focus on DC vaccines with greater potency administered to subjects with less tumor burden.
Collapse
Affiliation(s)
- W K Chia
- Department of Medical Oncology, National Cancer Centre, Singapore
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Toh HC, Chia WK, Sun L, Thng CH, Soe Y, Phoon YP, Yap SP, Lim WT, Tai WM, Hee SW, Tan SH, Leong SS, Tan EH. Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation. Bone Marrow Transplant 2010; 46:573-9. [PMID: 20661236 PMCID: PMC3072519 DOI: 10.1038/bmt.2010.161] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
While nonmyeloablative peripheral blood stem cell transplantation (NST) has shown efficacy against several solid tumors, it is untested in nasopharyngeal cancer (NPC). In a phase II clinical trial, 21 patients with pretreated metastatic NPC underwent NST with sibling PBSC allografts, using CY conditioning, thymic irradiation and in vivo T-cell depletion with thymoglobulin. Stable lymphohematopoietic chimerism was achieved in most patients and prophylactic CYA was tapered at a median of day +30. Seven patients (33%) showed partial response and three (14%) achieved stable disease. Four patients were alive at 2 years and three showed prolonged disease control of 344, 525 and 550 days. With a median follow-up of 209 (4-1147) days, the median PFS was 100 days (95% confidence interval (CI), 66-128 days), and median OS was 209 days (95% CI, 128-236 days). Patients with chronic GVHD had better survival-median OS 426 days (95% CI, 194-NE days) vs 143 days (95% CI, 114-226 days) (P=0.010). Thus, NST may induce meaningful clinical responses in patients with advanced NPC.
Collapse
Affiliation(s)
- H C Toh
- Department of Medical Oncology, National Cancer Centre, Singapore, Singapore.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Lim WT, Leong SS, Toh CK, Ang CS, Wong NS, Tan EH, Chowbay B. A phase I pharmacokinetic study of a liposomal formulation of paclitaxel administered weekly to Asian patients with solid malignancies. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.2581] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2581 Background: Genexol-PM is a sterile, lyophilized polymeric micellar formulation of paclitaxel which is devoid of Cremophor EL and hence is more tolerable and less toxic. This phase 1 study sought to determine the maximum tolerated dose and the pharmacokinetic profile of Genexol-PM in Asian cancer patients with solid malignancies. Methods: Patients (N=35) refractory to previous chemotherapy were enrolled in a phase 1, open-label, dose-escalating study to assess safety, tolerability ad pharmacokinetics of Genexol-PM administered as a 1h infusion on a weekly basis for 3 weeks followed by a resting week. The starting dose was 80mg/m2. Cohorts of 1–6 patients were treated at 100, 120, 140, 160, 180 and the maximum administered dose was 200 mg/m2. Results: The median age was 56 years (range: 39 - 67 years) and two thirds of the enrolled patients were male (67%). Twenty-three patients (96%) had received prior chemotherapy, including eleven patients (46%) who had previously received taxane-based chemotherapy. The majority of patients had lung, nasopharyngeal and breast cancers. DLT was reached at 200 mg/m2. The MTD was 180 mg/m2. Grade 3 granulocytopenia was common in patients receiving Genexol-PM at doses of 120 mg/m2 or higher in the first cycle. The most common grade 3 non-haematologic adverse events in cycle 1 were fatigue, myalgia and neuropathy and occurred mainly at dose level 7 (200 mg/m2) in 4%, 4% and 8% of the patients. Five (21%) patients had partial response, 9 (38%) had stable disease and seven (29%) patients had disease progression. The pharmacokinetics of Genexol-PM displayed dose-proportionality, with both Cmax and AUC0-∞ values increasing by approximately 4- and 3-fold as the dose of Genexol-PM was increased from 80mg/m2 to 200mg/m2 with no significant change in clearance. The median total-body clearance of Genexol-PM for all patients was 43.9 L/hr. Conclusions: The weekly regimen of Genexol-PM was found to be well-tolerated and responses were observed in patients with refractory tumours, including patients who had failed taxane-based chemotherapy previously. No significant financial relationships to disclose.
Collapse
|
12
|
Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, Aitini E, Carteni G, Riska H, Tsai YH, Abratt R. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2009; 20:1249-56. [PMID: 19276396 DOI: 10.1093/annonc/mdn774] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND The study compared the efficacy of a first-line treatment with day 1 i.v. vinorelbine (NVBiv) and day 8 oral vinorelbine (NVBo) versus docetaxel (DCT) in a cisplatin-based combination in advanced non-small-cell lung cancer, in terms of time to treatment failure (TTF), overall response, progression-free survival (PFS), overall survival (OS), tolerance and quality of life (QoL). METHODS Patients were randomly assigned to receive cisplatin 80 mg/m2 with NVBiv 30 mg/m2 on day 1 and NVBo 80 mg/m2 on day 8 every 3 weeks, after a first cycle of NVBiv 25 mg/m2 on day 1 and NVBo 60 mg/m2 on day 8 (arm A) or cisplatin 75 mg/m2 and DCT 75 mg/m2 on day 1 every 3 weeks (arm B), for a maximum of six cycles in both arms. RESULTS From 2 February 2004 to 1 January 2006, 390 patients were entered in a randomised study and 381 were treated. The patient characteristics are as follows (arms A/B): metastatic (%) 80.5/84.8; patients with three or more organs involved (%) 45.3/40.8; median age 59.4/62.1 years; male 139/146; squamous (%) 34.2/33.5; adenocarcinoma (%) 41.6/39.3; median TTF (arms A/B in months) [95% confidence interval (CI)]: 3.2 (3.0-4.2), 4.1 (3.4-4.5) (P = 0.19); overall response (arms A/B) (95% CI): 27.4% (21.2% to 34.2%), 27.2% (21.0% to 34.2%); median PFS (arms A/B in months) (95% CI): 4.9 (4.4-5.9), 5.1 (4.3-6.1) (P = 0.99) and median OS (arms A/B in months) (95% CI): 9.9 (8.4-11.6), 9.8 (8.8-11.5) (P = 0.58). The median survival for squamous histology was 8.87/9.82 months and for adenocarcinoma 11.73/11.60 months for arms A and B, respectively. Main haematological toxicity was grade 3-4 neutropenia: 24.4% (arm A) and 28.8% (arm B). QoL as measured by the Lung Cancer Symptom Scale was similar in both arms. CONCLUSIONS Both arms provided similar efficacy in terms of response, time-related parameters and QoL, with an acceptable tolerance profile. In the current Global Lung Oncology Branch trial 3, NVBo was shown to be effective as a substitute for the i.v. formulation. This can relieve the burden of the i.v. injection on day 8 and can optimise the hospital's resources and improve patient convenience.
Collapse
Affiliation(s)
- E H Tan
- Department of Medical Oncology, Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Delmar P, Tan EH, Pluzanska AG, Ramlau R, Reck M, McLoughlin P, Baselga J. MERIT: Analysis of differential gene expression in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated with erlotinib. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8046] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Ngeow JY, Gao F, Leong SS, Lim W, Toh C, Tan EH. Phase II study of weekly docetaxel as salvage therapy for disseminated nasopharyngeal carcinoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.6057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Wang Z, Lal S, Sandanaraj E, Lim WT, Leong SS, Tan EH, Chowbay B. Phase I dose finding study of Genexol-PM (G-PM) in Asian cancer patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.13512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Ma B, Tan EH, Mok T, Lam KC, Soo R, Leong SS, Wang LZ, Mo F, Chan AT, Goh BC. High incidence of symptomatic methemoglobinemia (metHb) in Asian patients (pts) treated with 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, triapine) and gemcitabine (GEM) in a second-line phase II trial of metastatic non-small cell lung cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18207 Background: Triapine (Vion Pharmaceuticals) is an inhibitor of ribonucleotide reductase that can enhance GEM uptake in GEM- resistant cell lines. Clinically significant metHb has been rarely reported with triapine & G6PD-deficient pts maybe more susceptible. This multicenter study evaluated the activity & safety of combined triapine-GEM in pts with metastatic NSCLC who had progressed despite prior response or disease stabilization to 1st line platinum-GEM regimen. Methods: Eligible pts were treated with triapine (105mg/m2) as 4-hr IV infusion, followed by GEM (1g/m2) over 30-min on days 1, 8 & 15, repeating every 28 days for 6 cycles. G6PD-deficient pts were excluded. Results: 6 males & 6 female Asian pts (median age: 65 yrs) received a median no. of 2 cycles (range 1–6 cycles). At a median follow-up of 4.6 mos, no response was seen. 4 pts had stable disease. Median time to progression was 3 mos (95% CI: 1.7–9.1 mos). Gr 3–4 toxicities included neutropenia (gr 3, 2 pts), hypoxia (gr 3, 3 pts) & dyspnea (gr 3, 1 pt). There were no treatment-related deaths & all pts remained alive at analysis. 4 pts developed symptomatic metHb during, or ≤ 4 hrs of stopping triapine. This was manifested as dyspnea &/or hypoxia, associated with an oxygen saturation of ≤90% at room air. Arterial metHb assay performed during the hypoxic episode showed a metHb level of up to 15% of total concentration of hemoglobin ([Hb]), which fell to < 5% of [Hb] within 4–6 hrs of stopping triapine. All pts recovered with conservative treatment & none required reversal with methylene blue. 3 out of the 4 pts were able to continue treatment after dose-reduction of triapine. Conclusions: The cause of the relatively high incidence of triapine-related symptomatic metHb was unclear in this Asian cohort. This study was terminated prematurely due to lack of response. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Ma
- Chinese University of Hong Kong, Hong Kong, China; National Cancer Center, Singapore; National University Hospital, Singapore, Singapore
| | - E. H. Tan
- Chinese University of Hong Kong, Hong Kong, China; National Cancer Center, Singapore; National University Hospital, Singapore, Singapore
| | - T. Mok
- Chinese University of Hong Kong, Hong Kong, China; National Cancer Center, Singapore; National University Hospital, Singapore, Singapore
| | - K. C. Lam
- Chinese University of Hong Kong, Hong Kong, China; National Cancer Center, Singapore; National University Hospital, Singapore, Singapore
| | - R. Soo
- Chinese University of Hong Kong, Hong Kong, China; National Cancer Center, Singapore; National University Hospital, Singapore, Singapore
| | - S. S. Leong
- Chinese University of Hong Kong, Hong Kong, China; National Cancer Center, Singapore; National University Hospital, Singapore, Singapore
| | - L. Z. Wang
- Chinese University of Hong Kong, Hong Kong, China; National Cancer Center, Singapore; National University Hospital, Singapore, Singapore
| | - F. Mo
- Chinese University of Hong Kong, Hong Kong, China; National Cancer Center, Singapore; National University Hospital, Singapore, Singapore
| | - A. T. Chan
- Chinese University of Hong Kong, Hong Kong, China; National Cancer Center, Singapore; National University Hospital, Singapore, Singapore
| | - B. C. Goh
- Chinese University of Hong Kong, Hong Kong, China; National Cancer Center, Singapore; National University Hospital, Singapore, Singapore
| |
Collapse
|
17
|
Ong ME, Yan X, Lau G, Tan EH, Panchalingham A, Leong BS, Ong VY, Tiah L, Yap S, Lim SH, Venkataraman A. Out-of-hospital Cardiac Arrests Occurring in Primary Health Care Facilities in Singapore. Acad Emerg Med 2007. [DOI: 10.1197/j.aem.2007.03.752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
18
|
Toh HC, Tan EH, Thng CH, Yap SP, Lee KM, Phoon YP, Chua S, Soe Y, Hee SW, Sun L. Nonmyeloablative allogeneic blood stem cell transplantation (NMBSCT) ± donor lymphocyte infusion (DLI) for chemorefractory advanced nasopharyngeal carcinoma (NPC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.2549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2549 Background: There is emerging clinical evidence for T cell immunotherapy in NPC. We report a NMBSCT regimen that induced mixed chimerism for DLI to potentially achieve a graft-versus-tumour effect (GVT) in NPC. Methods: 15 patients with advanced pretreated NPC were accrued to this prospective clinical trial. Our regimen comprised IV cyclophosphamide 50 mg/kg on day-5,-4,-3 and IV thymoglobuline on day-1, +1, +2 and +3 (n = 9) and then revised to IV thymoglobuline day-1, +1, +2, +3 (n = 6). Thymic radiation was given on day-1. G-CSF mobilized HLA-matched (n = 14) and 1-antigen-mismatched (n = 1) sibling PBSC were infused. DLI was initiated following taper of prophylactic cyclosporine (CyA). Results: Median age (n =15) was 49 yrs, median no. of metastatic organ sites was 3, mean no. of prior chemotherapy was 4 (range 2 - 8) and 14/15 had prior radiation. Median time to engraftment was 13 days and hospital stay was 17 days. Complete removal of prophylactic CyA was achieved for all patients at a median of day +28. DLI was given in 14 patients (median = 2, range 1 to 6). 4 patients were later re-started on GVHD immunosuppressive therapy. Two (13.3%) patients had acute GVHD (one Grade II and one fatal case who died on day+91). 3 patients developed chronic GVHD (20%), all controlled with short courses of standard immunosuppressive treatment. 11/15 died of PD, and 2/15 died from sepsis. 100-day TRM was 6.6%. 3/9 patients had donor graft loss. 6/6 patients on the revised protocol had stable and/or full donor chimerism. CMV antigenemia was 9/9 for the first regimen and 3/6 for the revised regimen (p = 0.044). Tumor response (RECIST) confirmed 40% PR, 33.3% SD and 40% PD, for a disease control rate of 73.3%. > day+100 anti-tumor response were observed in 5/15 patients (33.3%), implicating a GVT effect. 1 patient achieved a delayed PR on day+111 with stable donor chimerism of 19%. The longest surviving patient (36.5 mths) with multiple nodal, bone and lung metastasis achieved full donor chimerism and further tumor shrinkage at 8 mths post-NMBSCT. Conclusions: GVT is achievable with NMBSCT ± DLI in Stage IV NPC patients with a high disease control rate and acceptable GVHD. Early complete removal of prophylactic CyA was possible in all 15 patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. C. Toh
- National Cancer Centre, Singapore, Singapore; National University Hospital, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - E. H. Tan
- National Cancer Centre, Singapore, Singapore; National University Hospital, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - C. H. Thng
- National Cancer Centre, Singapore, Singapore; National University Hospital, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - S. P. Yap
- National Cancer Centre, Singapore, Singapore; National University Hospital, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - K. M. Lee
- National Cancer Centre, Singapore, Singapore; National University Hospital, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - Y. P. Phoon
- National Cancer Centre, Singapore, Singapore; National University Hospital, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - S. Chua
- National Cancer Centre, Singapore, Singapore; National University Hospital, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - Y. Soe
- National Cancer Centre, Singapore, Singapore; National University Hospital, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - S. W. Hee
- National Cancer Centre, Singapore, Singapore; National University Hospital, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - L. Sun
- National Cancer Centre, Singapore, Singapore; National University Hospital, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| |
Collapse
|
19
|
Poon D, Foo KF, Chew L, Leong SS, Wee J, Tan EH. Phase II Trial of Gemcitabine and Cisplatin Sequentially Administered in Asian Patients With Unresectable or Metastatic Non-small Cell Lung Cancer. Ann Acad Med Singap 2006. [DOI: 10.47102/annals-acadmedsg.v35n1p33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Introduction: The aim of this study was to assess toxicity and response in the sequential administration of gemcitabine followed by cisplatin in unresectable or metastatic non-small cell lung cancer.
Materials and Methods: Twenty-three patients were enrolled in this study. Gemcitabine was given at 1250 mg/m2 on days 1 and 8, for four 21-day cycles, followed by cisplatin 40 mg/m2 on days 1, 8 and 15, for three further 28-day cycles.
Results: There were 4 patients with partial responses, 5 patients with stable disease and 10 patients with progressive disease, giving a response rate of 21%. The median time to disease progression was 3.3 months. The median overall survival was 14.6 months. Toxicities graded 3 or 4 included anaemia (13.0%), neutropaenia (13.0%), supraventricular tachycardia (4.3%), and nausea and vomiting (4.3%).
Conclusion: Although these results show similar efficacy to single-agent treatment regimens, the low toxicity profile and promising survival outcome with this regimen are important points for consideration.
Key words: Anaemia, Neutropaenia, Supraventricular tachycardia
Collapse
Affiliation(s)
- D Poon
- National Cancer Centre, Singapore
| | - KF Foo
- National Cancer Centre, Singapore
| | - L Chew
- National Cancer Centre, Singapore
| | - SS Leong
- National Cancer Centre, Singapore
| | - J Wee
- National Cancer Centre, Singapore
| | - EH Tan
- National Cancer Centre, Singapore
| |
Collapse
|
20
|
Poon D, Foo KF, Chew L, Leong SS, Wee J, Tan EH. Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer. Ann Acad Med Singap 2006; 35:33-7. [PMID: 16470272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
INTRODUCTION The aim of this study was to assess toxicity and response in the sequential administration of gemcitabine followed by cisplatin in unresectable or metastatic non-small cell lung cancer. MATERIALS AND METHODS Twenty-three patients were enrolled in this study. Gemcitabine was given at 1,250 mg/m2 on days 1 and 8, for four 21-day cycles. RESULTS There were 4 patients with partial responses. 5 patients with stable disease and 10 patients with progressive disease, giving a response rate of 21%. The median time to disease progression was 3.3 months. The median overall survival was 14.6 months. Toxicities graded 3 or 4 included anaemia (13.0%), neutropaenia (13.0%), supraventricular tachycardia (4.3%), and nausea and vomiting (4.3%). CONCLUSION Although these results show similar efficacy to single-agent treatment regimens, the low toxicity profile and promising survival outcome with this regimen are important points for consideration.
Collapse
Affiliation(s)
- D Poon
- Department of Medical Oncology, National Cancer Centre, Singapore
| | | | | | | | | | | |
Collapse
|
21
|
Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2005; 49:233-40. [PMID: 16022917 DOI: 10.1016/j.lungcan.2005.03.029] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2004] [Revised: 03/02/2005] [Accepted: 03/07/2005] [Indexed: 11/27/2022]
Abstract
PURPOSE The objective of this trial was to compare two vinorelbine-based doublets with carboplatin (CBDCA-VC) or with gemcitabine (VG) in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). PATIENTS AND METHODS A total of 316 patients with advanced NSCLC previously untreated were randomized to either vinorelbine 30 mg/m(2) D1,8 with carboplatin AUC 5 D1 (VC) or vinorelbine 25mg/m(2) with gemcitabine (VG) 1000 mg/m(2) both given D1,8 every 3 weeks. The primary endpoint was response rate with secondary parameters being survival (OS), progression-free survival (PFS), tolerance and clinical benefit. RESULTS The median number of cycles was four in each arm with a total of 1268 cycles. The objective response (OR) on intent-to-treat was 20.8% in VC and 28% in VG (p=0.15). Median PFS was 3.9 months in VC and 4.4 months (mo) in VG (p=0.18). Median survival was significantly longer (p=0.01) for VG with 11.5 mo compared to 8.6 mo in VC with 1 year survival at 48.9 and 34.4%, respectively. Tolerance was better in the VG arm as compared to the VC patients. Four toxic deaths were recorded in the VC group. Clinical benefit response rate was 32.4% compared to 40.9% in 111 and 110 evaluable patients in VC and VG, respectively. CONCLUSION VG compared to VC resulted in a similar overall response rate, favourable median survival and a better toxicity profile. For non-cisplatin-based chemotherapy, VG is a useful alternative.
Collapse
Affiliation(s)
- E H Tan
- National Cancer Centre, 11 Hospital Drive, Singapore 169610, Singapore
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Leong SS, Wee J, Rajan S, Poon D, Toh CK, Lim D, Tay MH, Foo KF, Tan EH. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and leucovorin in patients with metastatic nasopharyngeal carcinoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - J. Wee
- Natl Cancer Ctr, Singapore, Singapore
| | - S. Rajan
- Natl Cancer Ctr, Singapore, Singapore
| | - D. Poon
- Natl Cancer Ctr, Singapore, Singapore
| | - C. K. Toh
- Natl Cancer Ctr, Singapore, Singapore
| | - D. Lim
- Natl Cancer Ctr, Singapore, Singapore
| | - M. H. Tay
- Natl Cancer Ctr, Singapore, Singapore
| | - K. F. Foo
- Natl Cancer Ctr, Singapore, Singapore
| | - E. H. Tan
- Natl Cancer Ctr, Singapore, Singapore
| |
Collapse
|
23
|
Wong NS, Foo KF, Poon D, Leong SS, Wong WK, Chan HS, Soo KC, Yap SP, Wee J, Cheung YB, Tan EH. Concurrent chemoradiotherapy followed by surgery in locally advanced squamous cell carcinoma of the oesophagus: a single centre experience. Ann Acad Med Singap 2005; 34:369-75. [PMID: 16021227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
INTRODUCTION Data on combined modality treatment for locally advanced squamous cell carcinoma of the oesophagus involving Asian patients are limited. MATERIALS AND METHODS A retrospective study of 56 consecutive patients with this condition treated with concurrent chemoradiotherapy followed by surgery in a single tertiary institution in Singapore was performed. RESULTS The median overall survival of the entire cohort was 14.1 months [95% confidence interval (CI); range, 8.6 to 19.6 months]. In patients who underwent successful oesophagectomy after chemoradiotherapy (n = 17), the median survival was 27.8 months compared to 9.8 months for those who did not have surgery (n = 39) (P = 0.046, log-rank test). The median time to first relapse for the entire cohort was 16.1 months (95% CI, 7.7 to 24.5 months). The time to first relapse was 23.9 months in the subgroup of patients with successful surgery and 12.1 months in the group which did not (P = 0.147, log-rank test). The high proportion of patients who were medically unfit for surgery or declined surgery may have conferred a selection bias. CONCLUSION Concurrent chemoradiotherapy followed by surgery is feasible in selected patients. The benefit of adding of surgery to chemoradiotherapy is still controversial and we await the results of randomised controlled trials comparing chemoradiotherapy with surgery versus chemoradiotherapy alone.
Collapse
Affiliation(s)
- N S Wong
- Department of Medical Oncology, National Cancer Centre, 11 Hospital Drive, Singapore 169610
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Zhou Q, Kibat C, Cheung YB, Tan EH, Ang P, Balram C. Pharmacogenetics of the epidermal growth factor receptor (EGFR) gene in Chinese, Malay and Indian populations. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Q. Zhou
- National Cancer Centre Singapore, Singapore, Singapore
| | - C. Kibat
- National Cancer Centre Singapore, Singapore, Singapore
| | - Y. B. Cheung
- National Cancer Centre Singapore, Singapore, Singapore
| | - E. H. Tan
- National Cancer Centre Singapore, Singapore, Singapore
| | - P. Ang
- National Cancer Centre Singapore, Singapore, Singapore
| | - C. Balram
- National Cancer Centre Singapore, Singapore, Singapore
| |
Collapse
|
25
|
Abratt RP, Szczesna A, Mattson K, Wernli M, Reiterer P, Hui R, Lizon J, Bertetto O, Reck M, Tan EH. Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patient benefit analysis. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. P. Abratt
- Groote Schuur Hospital, Cape Town, South Africa; Mazowieckie Centrum Leczenia, Otwock, Poland; Helsinki University Central Hospital, Helsinki, Finland; Onkologie/Hämatologie Kantonsspital, Aarau, Switzerland; Masaryk Hospital, Usti nad Labem, Czech Republic; Westmead Hospital, Sydney, Australia; Hospital San Juan de Alicante, San Juan de Alicante, Spain; AOS Giovanni Battista Molinette, Torino, Italy; Krankenhaus Grosshandorf, Grosshandorf, Germany; National Cancer Centre, Singapore, Singapore
| | - A. Szczesna
- Groote Schuur Hospital, Cape Town, South Africa; Mazowieckie Centrum Leczenia, Otwock, Poland; Helsinki University Central Hospital, Helsinki, Finland; Onkologie/Hämatologie Kantonsspital, Aarau, Switzerland; Masaryk Hospital, Usti nad Labem, Czech Republic; Westmead Hospital, Sydney, Australia; Hospital San Juan de Alicante, San Juan de Alicante, Spain; AOS Giovanni Battista Molinette, Torino, Italy; Krankenhaus Grosshandorf, Grosshandorf, Germany; National Cancer Centre, Singapore, Singapore
| | - K. Mattson
- Groote Schuur Hospital, Cape Town, South Africa; Mazowieckie Centrum Leczenia, Otwock, Poland; Helsinki University Central Hospital, Helsinki, Finland; Onkologie/Hämatologie Kantonsspital, Aarau, Switzerland; Masaryk Hospital, Usti nad Labem, Czech Republic; Westmead Hospital, Sydney, Australia; Hospital San Juan de Alicante, San Juan de Alicante, Spain; AOS Giovanni Battista Molinette, Torino, Italy; Krankenhaus Grosshandorf, Grosshandorf, Germany; National Cancer Centre, Singapore, Singapore
| | - M. Wernli
- Groote Schuur Hospital, Cape Town, South Africa; Mazowieckie Centrum Leczenia, Otwock, Poland; Helsinki University Central Hospital, Helsinki, Finland; Onkologie/Hämatologie Kantonsspital, Aarau, Switzerland; Masaryk Hospital, Usti nad Labem, Czech Republic; Westmead Hospital, Sydney, Australia; Hospital San Juan de Alicante, San Juan de Alicante, Spain; AOS Giovanni Battista Molinette, Torino, Italy; Krankenhaus Grosshandorf, Grosshandorf, Germany; National Cancer Centre, Singapore, Singapore
| | - P. Reiterer
- Groote Schuur Hospital, Cape Town, South Africa; Mazowieckie Centrum Leczenia, Otwock, Poland; Helsinki University Central Hospital, Helsinki, Finland; Onkologie/Hämatologie Kantonsspital, Aarau, Switzerland; Masaryk Hospital, Usti nad Labem, Czech Republic; Westmead Hospital, Sydney, Australia; Hospital San Juan de Alicante, San Juan de Alicante, Spain; AOS Giovanni Battista Molinette, Torino, Italy; Krankenhaus Grosshandorf, Grosshandorf, Germany; National Cancer Centre, Singapore, Singapore
| | - R. Hui
- Groote Schuur Hospital, Cape Town, South Africa; Mazowieckie Centrum Leczenia, Otwock, Poland; Helsinki University Central Hospital, Helsinki, Finland; Onkologie/Hämatologie Kantonsspital, Aarau, Switzerland; Masaryk Hospital, Usti nad Labem, Czech Republic; Westmead Hospital, Sydney, Australia; Hospital San Juan de Alicante, San Juan de Alicante, Spain; AOS Giovanni Battista Molinette, Torino, Italy; Krankenhaus Grosshandorf, Grosshandorf, Germany; National Cancer Centre, Singapore, Singapore
| | - J. Lizon
- Groote Schuur Hospital, Cape Town, South Africa; Mazowieckie Centrum Leczenia, Otwock, Poland; Helsinki University Central Hospital, Helsinki, Finland; Onkologie/Hämatologie Kantonsspital, Aarau, Switzerland; Masaryk Hospital, Usti nad Labem, Czech Republic; Westmead Hospital, Sydney, Australia; Hospital San Juan de Alicante, San Juan de Alicante, Spain; AOS Giovanni Battista Molinette, Torino, Italy; Krankenhaus Grosshandorf, Grosshandorf, Germany; National Cancer Centre, Singapore, Singapore
| | - O. Bertetto
- Groote Schuur Hospital, Cape Town, South Africa; Mazowieckie Centrum Leczenia, Otwock, Poland; Helsinki University Central Hospital, Helsinki, Finland; Onkologie/Hämatologie Kantonsspital, Aarau, Switzerland; Masaryk Hospital, Usti nad Labem, Czech Republic; Westmead Hospital, Sydney, Australia; Hospital San Juan de Alicante, San Juan de Alicante, Spain; AOS Giovanni Battista Molinette, Torino, Italy; Krankenhaus Grosshandorf, Grosshandorf, Germany; National Cancer Centre, Singapore, Singapore
| | - M. Reck
- Groote Schuur Hospital, Cape Town, South Africa; Mazowieckie Centrum Leczenia, Otwock, Poland; Helsinki University Central Hospital, Helsinki, Finland; Onkologie/Hämatologie Kantonsspital, Aarau, Switzerland; Masaryk Hospital, Usti nad Labem, Czech Republic; Westmead Hospital, Sydney, Australia; Hospital San Juan de Alicante, San Juan de Alicante, Spain; AOS Giovanni Battista Molinette, Torino, Italy; Krankenhaus Grosshandorf, Grosshandorf, Germany; National Cancer Centre, Singapore, Singapore
| | - E. H. Tan
- Groote Schuur Hospital, Cape Town, South Africa; Mazowieckie Centrum Leczenia, Otwock, Poland; Helsinki University Central Hospital, Helsinki, Finland; Onkologie/Hämatologie Kantonsspital, Aarau, Switzerland; Masaryk Hospital, Usti nad Labem, Czech Republic; Westmead Hospital, Sydney, Australia; Hospital San Juan de Alicante, San Juan de Alicante, Spain; AOS Giovanni Battista Molinette, Torino, Italy; Krankenhaus Grosshandorf, Grosshandorf, Germany; National Cancer Centre, Singapore, Singapore
| |
Collapse
|
26
|
Balram C, Tan EH, Zhou Q, Cheung YB, Kibat C, Leong SS. Pharmacogenetics of ABC transporters and drug metabolising enzymes and their influence on Irinotecan (CPT-11) elimination pathways in Asian cancer patients. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Balram
- National Cancer Centre, Singapore, Singapore
| | - E. H. Tan
- National Cancer Centre, Singapore, Singapore
| | - Q. Zhou
- National Cancer Centre, Singapore, Singapore
| | | | - C. Kibat
- National Cancer Centre, Singapore, Singapore
| | - S. S. Leong
- National Cancer Centre, Singapore, Singapore
| |
Collapse
|
27
|
Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, Bezjak A, Tu D, Santabárbara P, Seymour L. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7022] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. A. Shepherd
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - J. Pereira
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - T. E. Ciuleanu
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - E. H. Tan
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - V. Hirsh
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - S. Thongprasert
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - A. Bezjak
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - D. Tu
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - P. Santabárbara
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - L. Seymour
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| |
Collapse
|
28
|
Poon D, Chowbay B, Leong SS, Cheung YB, Toh CK, Tay MH, Lim WT, Tan EH. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma (NPC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. Poon
- National Cancer Centre, Singapore, Singapore
| | - B. Chowbay
- National Cancer Centre, Singapore, Singapore
| | - S. S. Leong
- National Cancer Centre, Singapore, Singapore
| | | | - C. K. Toh
- National Cancer Centre, Singapore, Singapore
| | - M. H. Tay
- National Cancer Centre, Singapore, Singapore
| | - W. T. Lim
- National Cancer Centre, Singapore, Singapore
| | - E. H. Tan
- National Cancer Centre, Singapore, Singapore
| |
Collapse
|
29
|
Toh CK, Heng D, Ong YK, Leong SS, Fong KW, Tan T, Wee J, Tan EH. A new prognostic index score for metastatic nasopharyngeal carcinoma: A validation study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. K. Toh
- National Cancer Centre, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - D. Heng
- National Cancer Centre, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - Y. K. Ong
- National Cancer Centre, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - S. S. Leong
- National Cancer Centre, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - K. W. Fong
- National Cancer Centre, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - T. Tan
- National Cancer Centre, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - J. Wee
- National Cancer Centre, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - E. H. Tan
- National Cancer Centre, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| |
Collapse
|
30
|
Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Lee KM, Yang E, Machin D. Phase III randomized trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage 3 and 4 nasopharyngeal cancer of the endemic variety. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5500] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. Wee
- National Cancer Center, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - E. H. Tan
- National Cancer Center, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - B. C. Tai
- National Cancer Center, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - H. B. Wong
- National Cancer Center, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - S. S. Leong
- National Cancer Center, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - T. Tan
- National Cancer Center, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - E. T. Chua
- National Cancer Center, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - K. M. Lee
- National Cancer Center, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - E. Yang
- National Cancer Center, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| | - D. Machin
- National Cancer Center, Singapore, Singapore; Clinical Trials & Epidemiology Research Unit, Singapore, Singapore
| |
Collapse
|
31
|
Bennouna J, Tan EH, Obrien M, Kosmidis P, Breton JL, Ottensmeier C, Tourani JM, Carballido F, Colin C, Douillard JY. Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7139] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. Bennouna
- Centre Rene Gauducheau, Saint Herblain, France; National Cancer Center, Singapore, Singapore; Royal Marsden Hospital, Sutton, United Kingdom; Hygeia Hospital, Athens, Greece; Hôpital de Belfort, Belfort, France; Southampton University Hospital, Southampton, United Kingdom; CHU de Poitiers, Poitiers, France; Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - E. H. Tan
- Centre Rene Gauducheau, Saint Herblain, France; National Cancer Center, Singapore, Singapore; Royal Marsden Hospital, Sutton, United Kingdom; Hygeia Hospital, Athens, Greece; Hôpital de Belfort, Belfort, France; Southampton University Hospital, Southampton, United Kingdom; CHU de Poitiers, Poitiers, France; Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - M. Obrien
- Centre Rene Gauducheau, Saint Herblain, France; National Cancer Center, Singapore, Singapore; Royal Marsden Hospital, Sutton, United Kingdom; Hygeia Hospital, Athens, Greece; Hôpital de Belfort, Belfort, France; Southampton University Hospital, Southampton, United Kingdom; CHU de Poitiers, Poitiers, France; Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - P. Kosmidis
- Centre Rene Gauducheau, Saint Herblain, France; National Cancer Center, Singapore, Singapore; Royal Marsden Hospital, Sutton, United Kingdom; Hygeia Hospital, Athens, Greece; Hôpital de Belfort, Belfort, France; Southampton University Hospital, Southampton, United Kingdom; CHU de Poitiers, Poitiers, France; Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - J.-L. Breton
- Centre Rene Gauducheau, Saint Herblain, France; National Cancer Center, Singapore, Singapore; Royal Marsden Hospital, Sutton, United Kingdom; Hygeia Hospital, Athens, Greece; Hôpital de Belfort, Belfort, France; Southampton University Hospital, Southampton, United Kingdom; CHU de Poitiers, Poitiers, France; Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - C. Ottensmeier
- Centre Rene Gauducheau, Saint Herblain, France; National Cancer Center, Singapore, Singapore; Royal Marsden Hospital, Sutton, United Kingdom; Hygeia Hospital, Athens, Greece; Hôpital de Belfort, Belfort, France; Southampton University Hospital, Southampton, United Kingdom; CHU de Poitiers, Poitiers, France; Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - J.-M. Tourani
- Centre Rene Gauducheau, Saint Herblain, France; National Cancer Center, Singapore, Singapore; Royal Marsden Hospital, Sutton, United Kingdom; Hygeia Hospital, Athens, Greece; Hôpital de Belfort, Belfort, France; Southampton University Hospital, Southampton, United Kingdom; CHU de Poitiers, Poitiers, France; Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - F. Carballido
- Centre Rene Gauducheau, Saint Herblain, France; National Cancer Center, Singapore, Singapore; Royal Marsden Hospital, Sutton, United Kingdom; Hygeia Hospital, Athens, Greece; Hôpital de Belfort, Belfort, France; Southampton University Hospital, Southampton, United Kingdom; CHU de Poitiers, Poitiers, France; Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - C. Colin
- Centre Rene Gauducheau, Saint Herblain, France; National Cancer Center, Singapore, Singapore; Royal Marsden Hospital, Sutton, United Kingdom; Hygeia Hospital, Athens, Greece; Hôpital de Belfort, Belfort, France; Southampton University Hospital, Southampton, United Kingdom; CHU de Poitiers, Poitiers, France; Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - J.-Y. Douillard
- Centre Rene Gauducheau, Saint Herblain, France; National Cancer Center, Singapore, Singapore; Royal Marsden Hospital, Sutton, United Kingdom; Hygeia Hospital, Athens, Greece; Hôpital de Belfort, Belfort, France; Southampton University Hospital, Southampton, United Kingdom; CHU de Poitiers, Poitiers, France; Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France
| |
Collapse
|
32
|
Abstract
The survival outcome of patients with systemic cancer differs significantly between individuals even within the same tumour type. We set out to illustrate this by analysing the factors determining survival in patients with metastatic disease from nasopharyngeal carcinoma (NPC) and to design a scoring system based on these prognostic factors. Patients referred between January 1994 and December 1999 were retrospectively analysed. Factors analysed included patient (age group, gender, performance status (BS) at diagnosis of metastases), disease (number of metastatic sites, specific metastatic sites, disease-free interval (DFI), metastases at presentation, presence of locoregional recurrence), and laboratory factors (leucocyte count, haemoglobin level, albumin level). Univariate and multivariable analyses were performed using the Cox proportion hazards model. A numerical score was derived from the regression coefficients of each independent prognostic variable. The prognostic index score (PIS) of each patient was calculated by totalling up the scores of each independent variable. Independently significant, negative prognostic factors were liver metastasis, lung metastasis, anaemia, poor PS, distant metastasis at initial diagnosis, and a DFI of <6 months. Three prognostic groups based on the PIS were obtained: (i) good risk (PIS=0-6); (ii) intermediate risk (7-10); (iii) poor risk (>or=11). The median survivals for these groups were 19.5, 10, and 5.8, months, respectively, (log rank test: P<0.0001). The variable prognosis of patients with disseminated NPC can be assessed by using easily available clinical information (patient, disease and laboratory factors). The PIS system will need to be validated on prospectively collected data of another cohort of patients.
Collapse
Affiliation(s)
- Y K Ong
- Department of Medical Oncology, National Cancer Centre, Singapore, Singapore
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Ho JCM, Tan EH, Leong SS, Wang CH, Sun Y, Li R, Wahid MIA, Jusuf A, Liao M, Guan Z, Handoyo P, Huang JS, Chan V, Luna G, Tsang KWT, Lam WK. A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer. Respir Med 2003; 97:796-803. [PMID: 12854629 DOI: 10.1016/s0954-6111(03)00033-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
AIMS To evaluate the efficacy and safety of docetaxel-cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). METHODS Chemotherapy-naïve patients with histologically confirmed TNM stage III or IV NSCLC were recruited from 12 Asian trial centers. Patients received docetaxel (75 mg/m2) and cisplatin (75 mg/m2) every 3 weeks for 6 cycles. RESULTS 130 of 146 patients were evaluable for efficacy (60% stage IV). Three complete and 58 partial responses were observed (overall response rate: 46.9%; 95% CI: 38.3-55.5%). Median time to progression was 6.9 months and median survival was 14.0 months; 1-year survival was 59.5%. Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 69.2%, 6.2% and 18.5% of patients, respectively. Grade 3/4 vomiting was observed in 13.7% and grade 3/4 neurosensory effects were observed in 2.7% of patients. There was one case of treatment-related death due to sepsis. CONCLUSION Docetaxel-cisplatin is an effective and well-tolerated treatment in Asian patients with NSCLC.
Collapse
Affiliation(s)
- James C M Ho
- Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Cheung YB, Ng GY, Wong LC, Koo WH, Tan EH, Tay MH, Lim D, Poon D, Goh C, Tan SB. Measuring quality of life in Chinese cancer patients: a new version of the Functional Living Index for Cancer (Chinese). Ann Acad Med Singap 2003; 32:376-80. [PMID: 12854381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
INTRODUCTION Since its translation into Chinese, the Functional Living Index for Cancer (FLIC) has not been widely received due to some of its difficulties. We modified its visual analogue scale (VAS) to an ordered categorical scale and changed some of the wording in the instrument. This study examined the measurement properties of the modified FLIC. MATERIALS AND METHODS The modified version of FLIC and the Functional Assessment of Cancer Therapy (FACT-G Chinese version 4) were filled in by 140 patients recruited from the National Cancer Centre Singapore. The patients' FLIC scores were compared with their clinical characteristics to establish known-group validity. Convergent and divergent validity of FLIC were examined by correlation analysis with FACT-G and its sub-scales. Cronbach's alpha and relative efficiency were also examined. RESULTS FLIC and most of its sub-scales could indicate a clear and statistically significant difference of quality of life (QOL) according to patients' performance status and treatment status. FLIC strongly correlated with FACT-G. The Physical, Psychological, and Symptoms sub-scales of FLIC converged to and diverged from FACT-G sub-scales as conceptually expected. Cronbach's alpha indicated a satisfactory level of reliability. FLIC appeared to be more efficient than FACT-G, meaning that a smaller sample size will be required for FLIC than for FACT-G to achieve the same research purpose. CONCLUSIONS The modified version of FLIC was found to have achieved satisfactory measurement properties. This is a user-friendly alternative to the original FLIC.
Collapse
Affiliation(s)
- Y B Cheung
- Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, 11 Hospital Drive, Singapore 169610.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Souquet PJ, Tan EH, Rodrigues Pereira J, Van Klaveren R, Price A, Gatzemeier U, Jaworski M, Burillon JP, Aubert D. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 2002; 13:1853-61. [PMID: 12453852 DOI: 10.1093/annonc/mdf316] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The standard doublet, vinorelbine-cisplatin, was compared with a triplet of vinorelbine-ifosfamide-cisplatin, in terms of survival, in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS From February 1998 to June 1999, 259 chemonaïve patients entered the study and were randomised to receive either vinorelbine-cisplatin (NP; vinorelbine 30 mg/m(2) on days 1, 8 and 15 with cisplatin 80 mg/m(2) on day 1) or vinorelbine-ifosfamide-cisplatin (NIP; vinorelbine 25 mg/m(2) on days 1 and 8, ifosfamide 3 g/m(2) on day 1 and cisplatin 75 mg/m(2) on day 1), with both regimens being repeated every 3 weeks. All patients had stage IV or relapsed disease and a performance score of 0 or 1. RESULTS The overall response rate was 34.6% for NP and 35.7% for NIP. Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively. A median of four cycles was administered in each arm. The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients). Four toxic deaths occurred in the NP arm and eight in the NIP arm. CONCLUSIONS The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile, although this is not statistically significant. This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC. The role of three-drug combinations remains questionable in this subset of patients.
Collapse
|
36
|
Foo KF, Tao M, Tan EH. Gastric carcinoma presenting with cellulitis-like cutaneous metastasis. Singapore Med J 2002; 43:37-8. [PMID: 12008775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
INTRODUCTION A case of carcinoma of the stomach presenting with cellulitis-like cutaneous metastasis is reported. CLINICAL PICTURE This patient was diagnosed to have early stage carcinoma of the prostate (T1bN0M0), which was treated with radiotherapy and hormonal therapy. He presented with an erythematous area of induration over the right neck a few weeks after the completion of radical radiotherapy. The CT scan of the neck showed features suggestive of cellulitis of the right cervical region. Due to the lack of response to intravenous antibiotics, a fine needle aspiration biopsy of the indurated area was done. This confirmed the presence of adenocarcinoma. Due to the presence of iron-deficiency anaemia and the positive occult blood test in the stool, an upper gastrointestinal endoscopy was done. This confirmed the presence of adenocarcinoma of the stomach of the signet-ring cell type. OUTCOME He had a rapid downhill course after the diagnosis and died four weeks after the diagnosis was made. CONCLUSION Carcinoma of the stomach can rarely present with cutaneous metastasis as a cellulitis-like picture.
Collapse
Affiliation(s)
- K F Foo
- Department of Medical Oncology, National Cancer Centre, Singapore.
| | | | | |
Collapse
|
37
|
Foo KF, Tan EH, Leong SS, Wee JTS, Tan T, Fong KW, Koh L, Tai BC, Lian LG, Machin D. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 2002; 13:150-6. [PMID: 11865813 DOI: 10.1093/annonc/mdf002] [Citation(s) in RCA: 110] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND We conducted two parallel phase II trials in chemonaïve and previously treated patients with metastatic nasopharyngeal carcinoma (NPC) to evaluate the tumour response, progression-free and overall survival, and toxicity of gemcitabine. PATIENTS AND METHODS Gemcitabine 1250 mg/m2 was given on days 1 and 8 of a 21-day cycle. Patients with an Eastern Cooperative Oncology Group performance status <2, adequate renal, hepatic and bone marrow function, and radiologically measurable NPC were eligible. RESULTS Twenty-five chemonaïve and 27 previously treated patients were enrolled. The overall response rate was 28% [95% confidence interval (CI) 14% to 48%] for the chemonaïve and 48% (95% CI 31% to 66%) for previously treated patients. Toxicities greater than or equal to grade 3 occurred in 15 (60%) chemonaïve and 13 (48%) previously treated patients. Neutropenia was uncommon in chemonaïve patients, but occurred in 37% of previously treated patients. The median time to progression was 3.6 months (range 0.9-7.9) for chemonaïve and 5.1 months (0.9-13.1) for previously treated patients. Median overall survival time was 7.2 months (1.4-15.6) and 10.5 months (2.4-15.0) for chemonaïve and previously treated patients, respectively. CONCLUSIONS Gemcitabine has moderate activity in NPC with minimal toxicity, and is also an effective salvage agent for patients who have failed or progressed after treatment with other agents.
Collapse
Affiliation(s)
- K F Foo
- Department of Medical Oncology, National Cancer Centre, Singapore, Singapore
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
BACKGROUND Patients who present with malignant pleural/malignant effusion without a definite primary site are not well described in the medical literature. In the course of our clinical practice, we have observed certain traits that are peculiar to patients with such a presentation. We have applied the term primary intrathoracic malignant effusion (PIME) to describe this condition. STUDY OBJECTIVES Patients must fulfill the following criteria before a diagnosis of PIME can be made: clinical presentation dominated by pleural/pericardial effusion; histologic proof of malignancy obtained from the pleura and/or pericardium; no definite primary site in the lungs or elsewhere from CT scan of the chest, chest radiograph, or physical and endoscopic examination; no history of malignancy; and no history of asbestos exposure. Exposure to environmental tobacco smoke (ETS) among the nonsmokers was examined in a case-control setting. METHODS We conducted a retrospective search of our database of patients who were referred to the Department of Medical Oncology with a diagnosis of pleural/pericardial effusion from January 1993 to January 2000. RESULTS Seventy-one of 200 patients from our database met the criteria. A significant majority of the patients were women (65%) and nonsmokers (72%). All patients had adenocarcinoma shown on biopsy. The majority of patients (63%) had disease localized to the intrathoracic serosal surfaces; the rest had distant metastases involving the lung (50%), bone (27%), liver (19%), brain (8%), and skin (4%). Six patients had two or more sites of distant metastases. There was a significant association with ETS exposure when compared to a control group comprised of patients with colonic cancer, matched for sex and age. The median survival was 10 months for patients with disease localized to the pleura/pericardium and 7 months for those with distant metastases. Thirty-eight patients (54%) received chemotherapy. All had platinum-based chemotherapy, except for three patients. The median survival for patients treated or not treated with chemotherapy was 12 months and 5 months, respectively. This difference in survival was statistically significant (p = 0.003). CONCLUSIONS PIME should be viewed as a distinct entity. Its etiology remains largely unknown, although exposure to environmental tobacco smoke may play a part. Platinum-based chemotherapy may have a positive biological effect on this disease. More studies are required to elucidate the epidemiology, possible etiologic factors, and treatment options for this group of patients.
Collapse
Affiliation(s)
- P Ang
- Department of Medical Oncology, National Cancer Center, Singapore
| | | | | | | | | | | | | |
Collapse
|
39
|
Leong SS, Tan EH, Khoo-Tan HS, Yang TL, Wee J, Tan SH, Poh WT, Tan NG. Recurrent nasopharyngeal carcinoma presenting as diffuse dermal lymphatic infiltration in the neck: three case reports. Head Neck 2001; 23:160-5. [PMID: 11303633 DOI: 10.1002/1097-0347(200102)23:2<160::aid-hed1011>3.0.co;2-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND Any malignancy has the propensity to metastasize to skin. The frequency of skin metastases vary in different tumors and occur in about 0.7% to 10% of all patients diagnosed with cancer. It is rare in nasopharyngeal carcinoma. METHOD Three cases of relapsed nasopharyngeal carcinoma with diffuse dermal involvement were described. Their clinical presentation, results of investigations, and response to treatment were reviewed. Literature review of similar forms of presentation was done by means of a MEDLINE search. RESULTS At the time of dermal relapse, all three patients had a uniform clinical picture of facial, periorbital, and lip swelling associated with stridor and dysphagia. Histologic findings showed dermal infiltrates of malignant cells, and CT scan showed diffuse infiltration of the subcutaneous tissue. Despite chemotherapy, the clinical course was relentless. CONCLUSION This report describes a presentation of disease that is underdiagnosed and heightens awareness of oncologists to this form of recurrence in nasopharyngeal carcinoma.
Collapse
Affiliation(s)
- S S Leong
- Department of Medical Oncology, National Cancer Centre, Singapore.
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Tan EH, Wee J, Ang PT, Fong KW, Leong SS, Khoo KS, Tan T, Lee KS, Eng P, Hsu A, Tan YK, Chua EJ, Ong YY. Induction chemotherapy followed by concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer. Acta Oncol 2000; 38:1005-9. [PMID: 10665753 DOI: 10.1080/028418699432266] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The favourable experience with the combination regimen of vinorelbine, ifosfamide and cisplatin (NIP) in patients with metastatic non-small cell lung cancer (NSCLC) has led to a protocol assessing this regimen as an induction treatment in patients with stage III unresectable NSCLC, followed by thoracic radiotherapy with concurrent daily cisplatin as a radiosensitizer. Two cycles of NIP were administered 21 days apart; each cycle comprised i.v. vinorelbine 25 mg/m2 on days 1 and 8, i.v. ifosfamide 3 g/m2 on day 1 with MESNA as uroprotection, and i.v. cisplatin 50 mg/m2 on day 1. Radical thoracic radiotherapy commenced on day 43 to a total dose of 64 Gy and i.v. cisplatin 6 mg/m2 was given concurrently prior to each fraction of radiation as a sensitiser. Two more cycles of NIP were given to patients who responded favourably to the induction treatment about 2 weeks after completion of radiation. Between July 1995 and July 1997, 44 patients were treated with this protocol. This treatment schedule was generally well tolerated. Grade 3-4 neutropenia occurred in 50% of the patients and neutropenic sepsis was seen in 8. Grade 3-4 oesophagitis was uncommon. Most of the patients were able to complete the induction and concurrent chemoradiotherapy phase. Major response occurred in 75% of the patients with 2 (4.5%) complete responses (CR). A total of 6 patients achieved CR after chemoradiotherapy. At a median follow-up of 35 months, the median overall survival for all patients was 15 months with a 3-year survival rate of 24%. The median overall survival for stage IIIA patients was 19 months with a 3-year survival rate of 39% in contrast to 13 months' median overall survival and only 15% 3-year survival rate for stage IIIB. The NIP regimen results in a high response rate in NSCLC and this treatment programme seems to benefit selected patients with stage III disease.
Collapse
Affiliation(s)
- E H Tan
- Department of Medical Oncology, National Cancer Centre, Singapore, Singapore
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Tan EH, Chua ET, Wee J, Tan T, Fong KW, Ang PT, Lee KS, Lee KM, Khoo-Tan HS, Leong SS, Ong YK, Foo KF, Sethi VK, Chua EJ. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal carcinoma: toxicities and preliminary results. Int J Radiat Oncol Biol Phys 1999; 45:597-601. [PMID: 10524411 DOI: 10.1016/s0360-3016(99)00210-2] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
PURPOSE Nasopharyngeal carcinoma (NPC) is endemic in Singapore. Nearly 60% of the patients diagnosed with NPC will present with locally advanced disease. The North American Intergroup study 0099 reported improved survival outcome in patients with locally advanced NPC who received combined chemoradiotherapy when compared to radiotherapy alone. Hence we explored the feasibility and efficacy of a similar protocol in our patients. METHODS AND MATERIALS Between June 1996 and December 1997, 57 patients were treated with the following schedule as described. Radical radiotherapy (RT) of 66-70 Gy to the primary and neck with cisplatin (CDDP) 25 mg/m2 on days 1-4 given by infusion over 6-8 hours daily on weeks 1, 4, and 7 of the RT. This is followed by a further 3 cycles of adjuvant chemotherapy starting from week 11 from the first dose of radiation (CDDP 20 mg/m2/d and 5-fluorouracil [5-FU] 1 gm/m2/d on days 1-4 every 28 days). RESULTS The majority of patients (68%) had Stage IV disease. About 54% of patients received all the intended treatment; 75% received all 3 cycles of CDDP during the RT phase and 63% received all three cycles of adjuvant chemotherapy. The received dose intensity of CDDP and 5-FU of greater than 0.8 was achieved in 58% and 60% of the patients respectively. Two treatment-related deaths due to reactivation of hepatitis B and neutropenic sepsis respectively, were encountered. At median follow-up of 16 months, 14 patients had relapsed, 12 systemically and 2 loco-regionally. CONCLUSION Due to the acceptable tolerability of such a protocol in our cohort of patients, we have embarked on a Phase III study to confirm the results of the 0099 Intergroup study in the Asian context.
Collapse
Affiliation(s)
- E H Tan
- Department of Medical Oncology, National Cancer Center, Singapore, Singapore.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
Between September 1994 and July 1997, 78 patients with advanced/metastatic, non-small cell lung cancer (NSCLC) were selected for the NIP (vinorelbine, ifosfamide, and cisplatin) protocol. The study group included 43 males; age range 34-74 years; median age 56 years; median follow-up for all patients was 14 months and for surviving patients, 30 months. Histological distribution included 55 adenocarcinomas (70.5%), 8 squamous cell carcinomas, and 9 large cell carcinomas. Stage distribution was 14 stage IIIB (malignant effusions) and 64 stage IV or recurrent metastatic; sites of metastasis were lungs, -26; liver-19; bones-27; brain-7; adrenals-3; distant nodes-2; skin-2. The NIP regimen was well tolerated by most of the patients but nausea/vomiting was noted in 55% of the cycles administered, most of them of grade 1-2 severity. Fifteen neutropenic episodes (5%) were encountered. Response to NIP was: 44 partial responses (56%); 1 complete response (1%); overall response, 58%. For stage IIIB, overall response was 36%, while for stage IV/metastatic, overall response was 63%. The median time to progression was 7 months for stage IIIB and 8 months for stage IV/metastatic disease and the overall median survival achieved was 14 months, with 60% of patients alive after one year. No significant difference in survival outcome was noted between patients with metastatic disease and those with stage IIIB (malignant effusion) disease. The NIP regimen has produced encouraging results in advanced NSCLC, as well as a favourable toxicity profile. The efficacy of NIP as a palliative tool should be assessed. A randomized trial to compare NIP with a two-drug combination of vinorelbine and cisplatin has been initiated.
Collapse
Affiliation(s)
- E H Tan
- Department of Medical Oncology, National Cancer Centre, Singapore General Hospital, Singapore.
| | | | | | | | | | | |
Collapse
|
43
|
Ong YK, Tan EH, Wee J, Goh CB, Fong KW, Lee KS, Chua EJ. Concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma of the undifferentiated type. Ann Acad Med Singap 1999; 28:525-8. [PMID: 10561766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
The result with radiotherapy alone in patients with locally advanced nasopharyngeal carcinoma (NPC) was disappointing. Encouraging results have been reported with the use of concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Hence, we decided to explore the use of this treatment schedule in patients who presented with locally advanced disease (UICC/AJCC classification system). Between July 1995 and March 1996, 14 patients with locally advanced NPC were treated with the following schedule: radiation therapy was given conventionally to a total of 66 to 70 Gy to both the nasopharynx and neck with or without parapharyngeal/intracavitary boost; chemotherapy consisted of intravenous cisplatin at 20 mg/m2/day and intravenous 5-flurouracil 1000 mg/m2/day, infused over 8 hours on days 1 to 4 during the first and fifth week of radiation therapy. Depending on the patient's tolerability and clinical assessment of toxicity, a third cycle of chemotherapy was planned 4 to 5 weeks after the second cycle, upon the completion of the radiotherapy. Twelve patients completed all intended treatment. Two patients failed to do so due to treatment-related mortality. The median follow-up duration was 30 months. Limiting toxicities were myelosuppression and oropharyngeal mucositis. The overall response rate was a 100% at both the primary and nodal sites of disease. The median disease-free survival was 21 months. Forty per cent of the patients were alive at 3 years. This treatment schedule was associated with an unacceptable treatment-related death rate. As a result, this protocol was terminated.
Collapse
Affiliation(s)
- Y K Ong
- Department of Medical Oncology, National Cancer Centre, Singapore
| | | | | | | | | | | | | |
Collapse
|
44
|
Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, Chua ET, Tan T, Khoo-Tan HS, Yang TL, Au E, Tao M, Ong YK, Chua EJ. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 1999; 10:235-7. [PMID: 10093695 DOI: 10.1023/a:1008390929826] [Citation(s) in RCA: 118] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
PURPOSE An earlier phase II trial of paclitaxel in patients with metastatic nasopharyngeal carcinoma (NPC) demonstrated a response rate of 22%. Hence we proceeded to study the combination of paclitaxel and carboplatin in these patients. PATIENTS AND METHODS The 21-day regimen was as follows: i.v. paclitaxel 175 mg/m2 over three hours preceded by standard premedications, followed by i.v. carboplatin dosed at AUC of six infused over one hour. Only chemotherapy-naive patients with histological diagnoses of undifferentiated carcinoma of the nasopharynx, systemic metastases and radiologically measurable lesions were eligible. RESULTS Thirty-two patients were accrued to this study. Twenty patients (62%) had at least two sites of metastasis. The main grade 3-4 toxicity was neutropenia (31%). Nine patients (28%) developed neutropenic sepsis, which caused the demise of one of them. Twenty-four patients (75%) responded to treatment, with one (3%) attaining a complete response. The median time to progression of disease was seven months and the median survival was 12 months. At one year, 52% of the patients were alive. CONCLUSIONS The combination of paclitaxel and carboplatin is an active regimen in NPC. Its convenience of administration and good tolerability make it an attractive alternative regimen to consider for patients with metastatic disease.
Collapse
Affiliation(s)
- E H Tan
- Department of Medical Oncology, National Cancer Center, c/o Singapore General Hospital
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Soh LT, Tan EH, Ang PT. Mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer. Singapore Med J 1998; 39:357-8. [PMID: 9844496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
BACKGROUND Chemotherapy can be used to palliate the symptoms in patients with advanced non-small cell lung cancer. PATIENTS Twenty-four chemo-naive patients with stage IIIB and IV non-small cell lung cancer were treated with the MIC regimen (mitomycin, ifosfamide and cisplatin). RESULTS The overall response rate was 33% (partial response) and median duration of response was 7 months (range 5 to 10 months). At median follow-up of 26 months, the median survival was 8 months, and 1-year survival was 29%. Toxicities were tolerable. CONCLUSION This appears to be a reasonable regimen for palliating advanced non-small cell lung cancer.
Collapse
Affiliation(s)
- L T Soh
- Department of Medical Oncology, Singapore General Hospital, Singapore
| | | | | |
Collapse
|
46
|
Abstract
BACKGROUND Despite its moderate anti-tumour activity in head and neck cancers there have been no reports on the activity of paclitaxel in patients with nasopharyngeal cancer, a highly chemosensitive tumour. A phase II study was thus initiated to determine the objective response rate and toxicity of paclitaxel in patients with previously untreated metastatic nasopharyngeal cancer. PATIENTS AND METHODS Twenty-four patients with previously untreated measurable metastatic nasopharyngeal carcinoma were accrued, one of them ineligible because of concomitant beta-blocker usage. Male:female ratio was 19:5, with a median age of 46 years. All had previously received radiotherapy but were chemotherapy-naïve. The great majority (20 of 24) had undifferentiated carcinoma. Paclitaxel (Anzatax, Faulding Pharmaceuticals) 175 mg/m2 was given intravenously over three hours every 21 days after premedication with oral dexamethasone and intravenous diphenhydramine and cimetidine. RESULTS There were five (21.7%) partial responses while eight patients remained stable. Median response duration was 7.5 months and median survival was 12 months. The main toxicity was haematological, with grade 1-2 neutropenia in 19% and grade 3-4 neutropenia in 4.5% of cycles. Three cycles were complicated by grade 3-4 anaemia and one patient required a blood transfusion. No thrombocytopenia was seen. Peripheral neuropathy was frequent (20 of 23 patients) but mild. Alopecia was complete in 14 patients. There were no cardiac toxicity or hypersensitivity reactions. CONCLUSIONS Paclitaxel is well tolerated even in previously irradiated patients with metastatic nasopharyngeal cancer. Single-agent activity was 22% and its inclusion into combination chemotherapy regimens should be studied.
Collapse
Affiliation(s)
- E Au
- Department of Medical Oncology, Singapore General Hospital, Singapore
| | | | | |
Collapse
|
47
|
Tan EH, Adelstein DJ, Saxton JP, Wood BG, Eliachar I, Van Kirk MA, Lavertu P. Concurrent chemoradiotherapy for salvage in relapsed squamous cell head and neck cancer. Cancer Invest 1997; 15:422-8. [PMID: 9316624 DOI: 10.3109/07357909709047581] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The results in 9 patients with unresectable recurrent squamous cell cancer of the head and neck who were treated with aggressive concurrent chemoradiotherapy are reported. Treatment consisted of one or two courses of chemotherapy with 5-fluorouracil 1000 mg/m2/day and cisplatin 20 mg/m2/day, both given as 4-day continuous intravenous infusions, concurrent with radiation therapy. Salvage radiation doses between 30 and 70 Gy were administered. Seven patients had previously undergone an attempt at curative surgery, and 7 had been treated with radiation doses between 52 and 72 Gy. The recurrent disease was locally confined in 3, locoregional in 5, and locoregional with metastases in 1 of the 9 patients. Treatment toxicity was significant and included mucositis, nausea/vomiting, and granulocytopenia, but there were no toxic deaths. Complete tumor clearance was possible in 6 of these 9 patients, and 5 patients remain disease-free at 41+, 43+, 45+, 47+, and 50+ months. Of these 5 patients, 4 had previously been treated with both surgery and radiation, while 1 had only undergone surgery. We conclude that aggressive chemotherapy and concurrent (re)irradiation can be given to patients with unresectable, recurrent, squamous cell cancer of the head and neck. Treatment is tolerable, and disease-free long-term survival is possible. Careful patient selection, however, is required.
Collapse
Affiliation(s)
- E H Tan
- Department of Hematology, Cleveland Clinic Foundation, Ohio, USA
| | | | | | | | | | | | | |
Collapse
|
48
|
Abstract
Tobacco and alcohol abuse are the major known risk factors for the development of squamous cell head and neck cancer (SCHNC). Information about this disease in nonsmokers, however, is limited. We retrospectively studied a group of 59 tobacco nonusers with SCHNC, diagnosed since 1986 at the Cleveland Clinic Foundation (CCF). Two objectives were defined: (a) to characterize this nonsmoking population of patients and identify any significant differences compared with a control population consisting of all patients diagnosed with SCHNC at the CCF between 1986 and 1993 and (b) to determine the prevalence of exposure to environmental tobacco smoke in this nonsmoking group of patients with SCHNC and compare it with the environmental tobacco-smoke exposure in a second, control population of non-SCHNC, nonsmoking patients matched for age, race, sex, and alcohol use. The group of nonsmoking patients with SCHNC was notable for only rare alcohol abuse, a preponderance of whites, and relatively fewer laryngeal primary tumors. There were significantly more women and more tongue primaries. When compared with the control population without cancer, the nonsmoking patients had a significantly higher risk of exposure to environmental tobacco smoke both in the home and in the workplace. We conclude that the tobacco nonuser who develops SCHNC is likely to be female and white and to have a primary tongue cancer. A significant association with environmental tobacco smoke exposure is suggested by our data.
Collapse
Affiliation(s)
- E H Tan
- Department of Hematology, Cleveland Clinic Foundation, Ohio 44195, U.S.A
| | | | | | | | | |
Collapse
|
49
|
Lim MK, Tan EH, Soh CS, Chang TL. Burkholderia pseudomallei infection in the Singapore Armed Forces from 1987 to 1994--an epidemiological review. Ann Acad Med Singap 1997; 26:13-7. [PMID: 9140571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Between 1987 and 1994, twenty-three cases of Burkholderia pseudomallei infection (melioidosis) were diagnosed in persons serving in the Singapore Armed Forces. There were four deaths resulting from complications of the infection. Unlike the situation in the general population, where the affected are mainly the elderly with underlying illness, the majority of cases in the Singapore Armed Forces were otherwise fit and healthy young servicemen. Serological surveys have shown the prevalence of the infection in Singapore to be 0.2% in the military as well as civilian population. As physical contact with soil is an unavoidable part of military training, military personnel continue to be at risk of exposure to this soil-related disease.
Collapse
Affiliation(s)
- M K Lim
- Defence Medical Research Institute, Ministry of Defence, Singapore
| | | | | | | |
Collapse
|
50
|
Affiliation(s)
- D J Adelstein
- Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Ohio 44195, USA
| | | | | |
Collapse
|